Oruka Therapeutics, Inc. Business Acquisition, Purchase Price Allocation, Assets Acquired (Liabilities Assumed), Net (Deprecated 2013-01-31)
Oruka Therapeutics, Inc. (ORKA) had Business Acquisition, Purchase Price Allocation, Assets Acquired (Liabilities Assumed), Net (Deprecated 2013-01-31) of $37.20 million as of 2009-01-27, per its 10-Q filed 2013-08-13.
Discontinued › Notes › Business Combinations
us-gaap:BusinessAcquisitionPurchasePriceAllocationAssetsAcquiredLiabilitiesAssumedNet · last filed 2013-08-13
- 2009-01-27: Business Acquisition, Purchase Price Allocation, Assets Acquired (Liabilities Assumed), Net (Deprecated 2013-01-31) $37.20M.
| Period end | Business Acquisition, Purchase Price Allocation, Assets Acquired (Liabilities Assumed), Net (Deprecated 2013-01-31) |
|---|---|
| 2009-01-27 | $37.20M 10-Q · filed 2013-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Veradermics, Inc (MANE) | United States | $4.839B |